Hodgkin Lymphoma News and Research

RSS

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle.

3 Dec 2019

Cancer patients have higher risk of cardiovascular death

A new study says that over 10% of patients with cancer die of unrelated cardiovascular disease (CVD) rather than their cancers.

25 Nov 2019

Risk of death from heart disease found to be higher in cancer patients

More than one in ten cancer patients do not die from their cancer but from heart and blood vessel problems instead, according to new research published in the European Heart Journal today. For some cancers, like breast, prostate, endometrial, and thyroid cancer, around half will die from cardiovascular disease (CVD).

25 Nov 2019

Radiation from CT scans can increase risk of leukemia, thyroid cancer

A new study in JNCI Cancer Spectrum finds that exposure to radiation from CT scans is associated with higher risks of developing thyroid cancer and leukemia.

19 Nov 2019

NCCN publishes new clinical practice guidelines for hematopoietic cell transplantation

Today, the National Comprehensive Cancer Network published new NCCN Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation, also known as stem cell transplant or historically as bone marrow transplant.

30 Oct 2019

Simple blood test can better identify patients at risk of relapse for B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, a cancer that begins in certain immune system cells and can occur almost anywhere in the body. More than 28,000 people are diagnosed with DLBCL each year.

21 Oct 2019

Study examines racial disparities in survival outcomes of pediatric patients with Hodgkin lymphoma

In what is believed to be the largest dataset study to date examining the role of race on survival outcome for pediatric patients with Hodgkin lymphoma, investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables.

18 Sep 2019

Scientists use CAR-T cells to reverse cardiac fibrosis

Scientists have used CAR-T cell therapy to treat cardiac fibrosis, a key part of heart disease and cardiac arrest.

12 Sep 2019

Cancer survivors could be at greater risk of cardiovascular diseases

Over the last few decades, medical progress has led to the survival of many more people with cancer. However, a new study published in The Lancet shows that this cohort has a higher risk of cardiovascular disease (CVD) than controls without cancer, due to a number of reasons.

21 Aug 2019

People who have a parent, sibling, or child with blood cancer have higher risk of disease

New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease.

9 Aug 2019

Research links inherited BRCA2 mutations with increased risk of childhood lymphoma

A report from St. Jude Children's Research Hospital links inherited mutations in the BRCA2 gene with an increased risk of developing non-Hodgkin lymphoma in children and adolescents.

25 Jul 2019

CAR-T cells used to target glioblastoma

Immunotherapy is the new weapon against cancers and building upon existing research, a team of researchers from the Massachusetts General Hospital have devised a way to make immunotherapy more effective in a deadly and common form of brain cancer called glioblastoma.

24 Jul 2019

Why it’s so hard to predict how much funding 9/11 first responders need

The idea of getting cancer from searching through the rubble of Ground Zero after the 9/11 attacks — and then standing guard over it for months — didn’t occur to Kevin Zweigbaum.

24 Jul 2019

Researchers develop new compound to block therapeutic target in aggressive blood cancer

Researchers at the UNC Lineberger Comprehensive Cancer Center have discovered a hyperactive cell signal that contributes to tumor growth in an aggressive blood cancer.

23 Jul 2019

Mathematical model helps quantify metastatic cell behavior

Cancer metastasis is a difficult stage to battle, especially if cancer cells are proliferating at a rapid pace. A new study reveals that metastatic cells change their shape to spread to other parts of the body. Researchers formulated a mathematical model to study metastatic cell behavior and similar cellular systems.

17 Jul 2019

AI-enabled device detects if targeted chemotherapy is working

A new portable device that utilizes artificial intelligence (AI) and biosensors can rapidly detect if cancer cells thrive after chemotherapy treatment.

17 Jul 2019

New chemoimmunotherapy regimen for aggressive form of lymphoma gets FDA approval

A cancer therapy based on the work of Ben Seon, PhD, at Roswell Park Comprehensive Cancer Center has been approved by the U.S. Food and Drug Administration for patients with an aggressive form of non-Hodgkin lymphoma.

24 Jun 2019

Disparities in race, ethnicity, and status affect progress in cancer survival rates in youth

A new study in JNCI Cancer Spectrum finds that dramatic increases in cancer survival in adolescents and young adults are undermined by continuing disparities by race, ethnicity, and socioeconomic status.

12 Jun 2019

First chemoimmunotherapy regimen approved by FDA for patients with diffuse large B-cell lymphoma

Today, the U.S. Food and Drug Administration granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

10 Jun 2019

Surgery can be beneficial for one type of primary central nervous system lymphoma

Through a systematic review of published studies going back 50 years, Johns Hopkins Medicine researchers say they have identified a distinct subtype of primary central nervous system lymphoma that should be considered for surgical removal, suggesting a major shift in how this type of tumor is evaluated and managed.

From Johns Hopkins Medicine 29 May 2019